You are here
Articles
Posted on Friday, July 26, 2013 - 5:16pm
By Dave Levitan
June 14, 2013
Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib(Drug information on imatinib) treatment did not relapse, according to results of a...
Posted on Friday, July 26, 2013 - 5:04pm
By Michael Mauro, MD1, Jerald Radich, MD2
July 25, 2013
1Memorial Sloan-Kettering Cancer Center, New York
2Fred Hutchinson Cancer Research Center, Seattle
Interviewed by Anna Azvolinsky, PhD
Chronic...
Posted on Monday, July 15, 2013 - 1:25pm
By Dave Levitan | July 12, 2013
While tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) in recent years, prognosis of the disease and prediction of response to those...
Posted on Wednesday, July 3, 2013 - 12:44pm
Zosia Chustecka
Jul 02, 2013
The European Commission has granted marketing authorization to ponatinib (Iclusig, Ariad Pharmaceuticals) as an orphan drug for use in certain leukemia patients who have stopped responding...
Posted on Monday, July 1, 2013 - 12:13pm
Michele Baccarani1,*, Michael W. Deininger2, Gianantonio Rosti3, Andreas Hochhaus4, Simona Soverini3, Jane F. Apperley5, Francisco Cervantes6, Richard E. Clark7, Jorge E. Cortes8, François Guilhot9, Henrik Hjorth-...
Posted on Monday, June 17, 2013 - 3:18pm
The Chronic Myelogenous Leukemia (CML) Society of Canada is pleased to provide open access to the paper, “Treating Chronic Myeloid Leukemia - Improving Management Through Understanding of the Patient Experience”.
Posted on Wednesday, June 12, 2013 - 10:45am
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)
2013...
Posted on Wednesday, June 12, 2013 - 10:38am
2013 ASCO Annual Meeting
Abstract Number: 7079
Citation: J Clin Oncol 31, 2013 (suppl; abstr 7079)
Author(s):
Hemant Malhotra, Pratibha Sharma, Shipra Bhargava, Om Singh Rathode, Bharti Malhotra, Vikram...
Posted on Wednesday, June 5, 2013 - 10:53am
" The tyrosine kinase inhibitors (TKIs) have irrevocably changed the care of chronic myeloid leukemia (CML) patients, dramatically changing the natural history of this disease.1-4 With multiple TKIs available, we now...
Posted on Wednesday, June 5, 2013 - 10:03am
Significance
Cancer stem cells (CSCs) frequently acquire the ability to self-renew and persist in their hosts by coopting normal stem cell programs. Blast crisis (BC) chronic myeloid leukemia is a prototypic example, as...
Posted on Saturday, June 1, 2013 - 9:14pm
Sebastian Francis, Claire Lucas, Steven Lane, Lihui Wang, Sarah Watmough, Katy Knight, Jo Bell, Mohammed Kaleel-Rahman, Edwin Lee, David O’Brien, Nauman M. Butt, Walid Sadik, Lally De Soysa, Jim R.C. Seale, Rahuman...
Posted on Sunday, May 12, 2013 - 7:23pm
Susan Branford1,2,3, David T. Yeung1,2,4, David M. Ross2,4,5, Jodi A. Prime1, Chani R. Field1, Haley K. Altamura1, Alexandra L. Yeoman1, Jasmina Georgievski1, Bronte A. Jamison1, Stuart Phillis1, Brad Sullivan1...
Posted on Sunday, May 12, 2013 - 7:19pm
Min Tang1, Mithat Gonen2, Alfonso Quintas-Cardama3, Jorge Cortes3, Hagop Kantarjian3, Chani Field4, Timothy P. Hughes4, Susan Branford4, and Franziska Michor1
Posted on Friday, April 26, 2013 - 1:53pm
Blood First Edition Paper, prepublished online April 25, 2013; DOI 10.1182/blood-2013-03-490003
Posted on Wednesday, April 17, 2013 - 5:53pm
Michael Kaufman | March 26, 2013
'While WT1 is overexpressed in leukemias and other cancers, including myeloma, and breast, ovarian, and colorectal cancers, it is found in few healthy cells, which makes side effects...
- ‹ previous
- 14 of 33
- next ›